A novel function of STAT3β in suppressing interferon response
... improves outcome in acute myeloid leukemia
Recent publication
The Division of Pharmakology led by Prof. Dr Dagmar Stoiber Sakaguchi is investigating the role of the signal transducer and transcription activator 3 (STAT3) in acute myeloid leukaemia, a malignant cancer of the haematopoietic system. The research group was able to show a favourable role of the STAT3beta subgroup on the survival rate in the mouse model and confirm their data on cells from patients with acute myeloid leukaemia. Their results provide valuable information for the use of the ratio of STAT3beta to STAT3alpha messenger RNA as a prognostic biomarker and as a possible target for personalised therapies. The work was supported by the Austrian Science Fund, the Gesellschaft für Forschungsförderung NÖ GmbH, the City of Vienna Fund for Innovative Interdisciplinary Cancer Research and the Italian Society for Cancer Research, among others. Thanks to open access funding from the Karl Landsteiner Private University, the work has been published freely accessible in the journal ‘Cell Death and Disease’.
Edtmayer, S, Witalisz-Siepracka, A, Zdársky, B, Heindl, K, Weiss, S, Eder, T, Dutta, S, Graichen, U, Klee, S, Sharif, O, Wieser, R, Győrffy, B, Poli, V, Casanova, E, Sill, H, Grebien, F & Stoiber, D 2024, 'A novel function of STAT3β in suppressing interferon response improves outcome in acute myeloid leukemia', Cell Death and Disease, vol. 15, no. 5, pp. 369. https://doi.org/10.1038/s41419-024-06749-9